Jazz Pharmaceuticals Corp (JAZZ) - Long-Term Debt to Capital Coefficient

Jazz Pharmaceuticals focuses on developing unique oncology and neurology medications, sustaining profits through orphan drugs. The company is also implementing environmental standards by upgrading facilities to protect nature. This price chart on the GURU.Markets platform illustrates the asset's dynamics, where the metric stands at 0.73. Steady interest in sleep therapy and the global expansion of sales markets create a positive growth trajectory.

This indicator measures the ratio of long-term liabilities to equity, allowing for an assessment of the actual financial burden and the stability of the business's financing structure. By analyzing financial leverage based on long-term debt, an investor can see how strategic acquisitions in oncology and neurology to protect Jazz Pharmaceuticals (JAZZ) revenues from patent expirations have impacted the debt load, confirming the effectiveness of capital management.